We are live on ! Find out more
SCV

Sands Capital Ventures Portfolio holdings

AUM $614M
1-Year Est. Return 19.92%
This Fund
S&P 500
This Quarter Est. Return
-21.07%
1 Year Est. Return
+19.92%
3 Year Est. Return
+166.76%
5 Year Est. Return
+157.76%
10 Year Est. Return
–
AUM
$364M
AUM Growth
-$114M
Cap. Flow
+$17.7M
Cap. Flow %
4.86%
Top 10 Hldgs %
90.27%
Holding
19
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$25M
2
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
+$3.63M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 43.47%
2 Technology 28.23%
3 Consumer Discretionary 10.6%
4 Financials 9.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PATH icon
1
UiPath
PATH
$8.3B
$69.3M 19.04%
3,811,779
– –
DICE
2
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$48.9M 13.42%
3,148,970
– –
DASH icon
3
DoorDash
DASH
$94B
$38.6M 10.6%
601,454
– –
NU icon
4
Nu Holdings
NU
$73.6B
$34.2M 9.38%
9,136,835
– –
SNOW icon
5
Snowflake
SNOW
$114B
$29.8M 8.2%
214,621
– –
KRTX
6
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$21.9M 6.01%
172,895
-95,000
-35% -$10.9M
TXG icon
7
10x Genomics
TXG
$7.31B
$21.8M 5.99%
+481,770
New +$25M
CINC
8
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$17.9M 4.91%
950,000
– –
ABOS icon
9
Acumen Pharmaceuticals
ABOS
$193M
$16.1M 4.41%
3,417,075
– –
OLK
10
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$10.7M 2.94%
705,514
+280,000
+66% +$3.63M
MASS icon
11
908 Devices
MASS
$414M
$6.72M 1.85%
326,427
– –
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.04B
$3.8M 1.04%
260,000
– –
RGEN icon
13
Repligen
RGEN
$9.42B
$3.66M 1.01%
22,544
– –
IOT icon
14
Samsara
IOT
$23.2B
$3.64M 1%
326,000
– –
TSHA icon
15
Taysha Gene Therapies
TSHA
$1.94B
$2.7M 0.74%
724,873
– –
CADL icon
16
Candel Therapeutics
CADL
$897M
$2.63M 0.72%
811,737
– –
SPRB
17
Spruce Biosciences
SPRB
$151M
$1.37M 0.38%
10,493
– –
ABSI icon
18
Absci
ABSI
$1.58B
$192K 0.05%
57,804
– –

Similar funds

T2I
Turim 21 Investimentos Rio De Janeiro, Brazil $613M AUM 14.25% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $613M AUM 30.37% 1-Year Est. Return
MKA
M. Kulyk & Associates Decatur, Georgia $613M AUM 22.75% 1-Year Est. Return
CSIA
Conrad Siegel Investment Advisors Harrisburg, Pennsylvania $615M AUM 21.19% 1-Year Est. Return
ATFA
All Terrain Financial Advisors Coon Rapids, Minnesota $615M AUM 30.42% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $615M AUM 25.07% 1-Year Est. Return
FWM
Fonville Wealth Management Richmond, Virginia $612M AUM 18.82% 1-Year Est. Return
FSA
Financial Security Advisor Virginia Beach, Virginia $615M AUM 26.08% 1-Year Est. Return

Sands Capital Ventures's Q2 2022 Portfolio in Review

As of Q2 2022, Sands Capital Ventures held 19 positions worth $364M, down 24% from $479M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Sands Capital Ventures deployed $17.7M of net new capital in Q2 2022, opening 1 new position and adding to 1 existing holding. Its largest new stake was 10x Genomics: 481,770 shares worth $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 33% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Karuna Therapeutics, Inc. Common Stock, an estimated $10.9M trimmed.

  • Sands Capital Ventures's largest Q2 2022 buy was 10x Genomics: 481,770 shares worth $21.8M.
  • Sands Capital Ventures added most to Olink Holding AB (publ) American Depositary Shares in Q2 2022, an estimated $3.63M increase.
  • Sands Capital Ventures's biggest Q2 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $10.9M.
  • Sands Capital Ventures's ten largest holdings make up 90% of its $364M portfolio in Q2 2022.
  • Sands Capital Ventures opened 1 new position and closed 0 in Q2 2022.
  • Sands Capital Ventures's portfolio value fell 24% quarter-over-quarter to $364M.

Based on Sands Capital Ventures's 13F filing for Q2 2022, filed 12 Aug 2022.